Harmine (Beta-Carboline Alkaloid · MAO-A Inhibitor · DYRK1A · Neuroprotective)

Compound	Harmine
Chemical class	Alkaloid — Indole (β-Carboline; Harmala Alkaloid)
CAS	442-51-3
Primary source	Peganum harmala (Syrian rue / harmal), Banisteriopsis caapi (ayahuasca vine)
Key applications	MAO-A inhibitor, neuroprotective, antidiabetic (DYRK1A), antidepressant research
Claim strength	Moderate
Typical form	Peganum harmala seed extract; harmine isolate
Buy from Herbuno	Harmal Seed Extract Powder - Peganum harmala → Harmal Oil Soluble Extract - Peganum harmala →

Commercial source: Peganum harmala (harmal) seed extract is commercially available, with harmine as the primary beta-carboline alkaloid alongside harmaline and tetrahydroharmine. See sourcing options below. Traditional use: Peganum harmala (harmal, Syrian rue) seeds and roots have been used for millennia across North Africa, Middle East, Central Asia, and South Asia in traditional medicine for a wide range of applications including anthelmintic, antimicrobial, abortifacient, psychoactive ritual use, and as a dye plant. In Ayurveda and Unani medicine, harmal preparations are used for fever, inflammation, and nervous system conditions. Banisteriopsis caapi (the ayahuasca vine in South American traditions) contains harmine and related alkaloids responsible for the MAO-inhibiting component of ayahuasca. Research trajectory: Harmine has attracted significant pharmaceutical research for its DYRK1A (dual-specificity tyrosine-regulated kinase 1A) inhibition — which has been proposed to promote pancreatic beta-cell regeneration, a potentially transformative mechanism for type 1 and type 2 diabetes treatment. Additionally, MAO-A inhibitory antidepressant activity and neuroprotective mechanisms are well-characterised. See sourcing options below.

---

Evidence for Harmine Applications

MAO-A inhibition and antidepressant: Harmine is a reversible MAO-A inhibitor with documented antidepressant activity in animal models comparable to pharmaceutical MAOIs and tricyclic antidepressants. MAO-A inhibition increases serotonin, dopamine, and norepinephrine levels by preventing their catabolism. This is the same mechanism as MAOI antidepressant drugs. At supplement doses from Peganum harmala extract, MAO-A inhibition is significant and requires dietary tyramine restriction advisory language (see drug interaction FAQ). Claim strength: Moderate (strong preclinical; limited human antidepressant data).

DYRK1A inhibition — beta-cell regeneration: Harmine is a potent DYRK1A inhibitor that promotes human pancreatic beta-cell proliferation in vitro and in human islet preparations — a potentially groundbreaking mechanism for diabetes regenerative therapy. Published in high-impact journals, this discovery has generated significant research interest. Early human tissue studies confirm beta-cell proliferation. No human clinical outcomes data exist yet. Claim strength: Emerging (compelling mechanism; preclinical/ex vivo stage; no human efficacy data).

Neuroprotective and neurogenesis: Harmine promotes hippocampal neurogenesis, activates BDNF/TrkB signalling, and reduces neuroinflammation. Antidepressant effects in animal models are partly mediated by neurogenesis rather than solely MAO inhibition. Claim strength: Moderate.

---

Dosage & Formulator Specification

Drug interaction priority: Harmine’s MAO-A inhibitory activity creates significant drug interaction potential. Before considering dosage, formulators must understand: at typical Peganum harmala extract doses providing >5 mg harmine, tyramine dietary restrictions (cheese, aged meats, wine, fermented foods) are advisable as clinically prudent precautions — the same restrictions required for pharmaceutical MAOI antidepressants. Interactions with serotonergic medications (SSRIs, triptans) risk serotonin syndrome. Interactions with sympathomimetics (ephedrine, pseudoephedrine) risk hypertensive crisis. These are not theoretical concerns but practical pharmacological risks at meaningful harmine doses.

For formulations containing Peganum harmala extract, maintain harmine content at levels where the MAO-A inhibitory contribution is sub-clinical for dietary tyramine interactions (typically <3 mg harmine per serving). Request harmine content quantification by HPLC on all Peganum harmala extract CoAs. Include comprehensive drug interaction advisory language on any harmine-containing product label.

---

Frequently Asked Questions — Harmine

Is harmine psychoactive at supplement doses?
Harmine itself is psychoactive at higher doses — it is the primary MAO-inhibiting alkaloid in ayahuasca vine that makes the DMT in ayahuasca preparations orally active. At typical supplement doses from Peganum harmala extract (below 20–30 mg harmine), the psychoactive effects are sub-threshold. The MAO inhibitory effects (tyramine interaction risk, drug interactions) are present at lower doses than the hallucinogenic threshold. Supplement products should not be positioned for psychoactive applications.

Is harmine relevant to Parkinson’s disease?
Harmine’s DYRK1A inhibition has been studied in Parkinson’s models as a neuroprotective mechanism. Additionally, environmental harmine exposure has been investigated in epidemiological studies — populations with higher dietary harmine exposure (from Peganum harmala-containing foods) show different Parkinson’s incidence patterns in some studies. The relationship is complex and not established as causative or protective definitively.

What makes harmine’s DYRK1A inhibition a breakthrough in diabetes research?
Beta-cell destruction or dysfunction underlies both type 1 and type 2 diabetes. No current treatment regenerates lost beta-cells. Harmine’s ability to induce human beta-cell proliferation — confirmed in human pancreatic islet preparations — represents the first botanical compound shown to directly stimulate human beta-cell division. This has generated enormous interest in the diabetes research community, though clinical translation to human in vivo beta-cell regeneration remains to be demonstrated.

Does harmine interact with antidepressant medications?
Yes — significantly. Harmine’s reversible MAO-A inhibition creates serotonin syndrome risk when combined with SSRIs, SNRIs, TCAs, triptans, and other serotonergic agents. It also creates hypertensive crisis risk with sympathomimetics and some over-the-counter cold medications. These are the same interactions as pharmaceutical MAOI antidepressants (phenelzine, tranylcypromine). Products containing meaningful harmine doses must carry comprehensive drug interaction warnings.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery